Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis
Launched by NOVARTIS · Sep 7, 2005
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of primary hip osteoarthritis
- • Qualifying pain intensity in the hip joint
- • Requiring NSAID therapy
- Exclusion Criteria:
- • Rheumatoid arthritis or other inflammatory joint disease
- • Disease or disorder that may interfere with pain assessment of the hip
- • Open knee/hip surgery within the last year
- • Past history of heart attack, stroke or angina (chest pain)
- • Liver disorder
- • History of severe adverse reactions of any kind under lumiracoxib or celecoxib treatment
- • Other protocol-defined exclusion criteria may apply.
About Novartis
Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
East Hanover, New Jersey, United States
Multiple Cities, , Canada
Multiple Cities, , Germany
Multiple Cities, , Italy
Multiple Cities, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials